Aimei Health Technology Co., Ltd (AFJK) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AFJK SEC filings page.
This page shows Aimei Health Technology Co., Ltd (AFJK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Reported profits do not reflect operating strength: cash outflows continue while shrinking assets and negative equity leave liabilities carrying the structure.
The reported net income remained positive in both FY2024 and FY2025, yet operating activities used$672K and$565K , respectively. That gap, alongside operating losses of$1.1M and$836K , indicates that accounting earnings are not being produced by the core operation or converted into cash.
The balance sheet contracted sharply: total assets fell from
Short-term liquidity is exceptionally tight: FY2025 current assets were only
Financial Health Signals
Aimei Health Technology Co., Ltd does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Aimei Health Technology Co., Ltd passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Aimei Health Technology Co., Ltd used $0.53 of operating cash (-$565K OCF vs $1.1M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
Aimei Health Technology Co., Ltd reported -$83K in net income in Q2 2026. This represents a decrease of 119.6% from the same quarter a year earlier. Against the prior quarter it is down 283.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Aimei Health Technology Co., Ltd held $1K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
AFJK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, EBITDA, Interest Expense, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
AFJK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.5M-71.9% | $12.3M-71.8% | $12.1M-83.6% | $45.5M-37.5% | $44.6M-38.0% | $43.6M-38.8% | $73.8M+4.7% | $72.8M |
| Current Assets | $44K-1.5% | $19K+133.2% | $3K-90.4% | $25K-79.9% | $45K-78.2% | $8K-98.3% | $30K-94.8% | $124K |
| Cash & Equivalents | $1K-31.4% | $19K+152.1% | $3K-89.6% | $3K-97.1% | $2K-98.6% | $7K-98.2% | $28K-95.1% | $104K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $17.0M-64.1% | $16.5M-64.1% | $16.2M-78.5% | $48.9M-33.5% | $47.4M-34.6% | $46.0M-35.8% | $75.3M+6.6% | $73.6M |
| Current Liabilities | $3.8M+73.4% | $3.5M+108.7% | $3.4M+312.7% | $2.8M+1102.1% | $2.2M+1890.7% | $1.7M+2048.2% | $817K+3188.9% | $231K |
| Non-Current Liabilities | $13.2M-70.8% | $13.0M-70.7% | $12.8M-82.8% | $46.1M-37.1% | $45.2M-37.6% | $44.3M-38.1% | $74.5M+5.5% | $73.4M |
| Total Equity | -$4.5M-56.8% | -$4.2M-76.9% | -$4.1M-174.9% | -$3.4M-331.6% | -$2.9M-379.1% | -$2.4M-722.8% | -$1.5M-1000.9% | -$797K |
| Retained Earnings | -$4.5M-56.8% | -$4.2M-76.9% | -$4.1M-174.8% | -$3.4M-331.5% | -$2.9M-378.9% | -$2.4M-722.3% | -$1.5M-999.3% | -$797K |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
AFJK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$157K+22.2% | -$75K+66.7% | -$43K+77.8% | -$96K-78.2% | -$202K+21.3% | -$224K-34.2% | -$195K | -$54K |
| Investing Cash Flow | -$103K+77.1% | -$69K-100.2% | $33.7M | -$450K | -$450K | $30.8M | N/A | N/A |
| Financing Cash Flow | $243K-62.4% | $159K+100.5% | -$33.6M | $547K | $647K | -$30.6M | N/A | N/A |
| Share Buybacks | N/A | N/A | $34.1M | $0 | $0 | $31.3M | N/A | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid.
AFJK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$4.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Aimei Health Technology Co., Ltd AFJK | FY2025 | N/A | $1.1M | N/A | $38.3M | — |
| Cayson Acquisition Corp CAPN | FY2025 | $4.9M | $3.0M | 62.0% | $59.5M | 24/100 |
| Rising Dragon Acquisition Corp. RDAC | FY2025 | N/A | $1.6M | N/A | $32.7M | — |
| Eureka Acquisition Corp Unit EURKU | FY2025 | N/A | $1.4M | N/A | N/A | — |
| Flag Ship Acquisition Corp. Unit FSHPU | FY2025 | $2.5M | $1.8M | 73.5% | N/A | 16/100 |
| DT Cloud Star Acquisition Corporation Units DTSQU | FY2025 | $2.7M | $2.1M | 79.5% | N/A | 28/100 |
Where Aimei Health Technology Co., Ltd Ranks
Frequently Asked Questions
Is Aimei Health Technology Co., Ltd profitable?
Yes, Aimei Health Technology Co., Ltd (AFJK) reported a net income of $1.1M in fiscal year 2025.
What is Aimei Health Technology Co., Ltd's operating cash flow?
Aimei Health Technology Co., Ltd (AFJK) recorded an outflow of $565K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Aimei Health Technology Co., Ltd's total assets?
Aimei Health Technology Co., Ltd (AFJK) had $12.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Aimei Health Technology Co., Ltd's current ratio?
Aimei Health Technology Co., Ltd (AFJK) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Aimei Health Technology Co., Ltd's return on assets (ROA)?
Aimei Health Technology Co., Ltd (AFJK) had a return on assets of 8.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aimei Health Technology Co., Ltd's P/E ratio?
Aimei Health Technology Co., Ltd (AFJK) trades at 36.2x earnings, its market capitalization divided by net income of $1.1M net income, FY2025. The market capitalization is $38.3M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Aimei Health Technology Co., Ltd's price-to-sales ratio?
Aimei Health Technology Co., Ltd (AFJK) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $38.3M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Aimei Health Technology Co., Ltd's debt-to-equity ratio negative or not reported?
Aimei Health Technology Co., Ltd (AFJK) has negative shareholder equity of -$4.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aimei Health Technology Co., Ltd's Piotroski F-Score?
Aimei Health Technology Co., Ltd (AFJK) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aimei Health Technology Co., Ltd's earnings high quality?
For every $1 of reported earnings, Aimei Health Technology Co., Ltd (AFJK) used $0.53 of operating cash (-$565K OCF vs $1.1M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.